Production (Stage)
Sarepta Therapeutics, Inc.
SRPT
$37.60
-$1.01-2.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 59.15% | 52.97% | 48.45% | 49.98% | 43.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.15% | 52.97% | 48.45% | 49.98% | 43.83% |
| Cost of Revenue | 78.73% | 9.33% | -0.15% | -10.56% | -6.91% |
| Gross Profit | 10.95% | 261.01% | 742.24% | 1,124.58% | 520.45% |
| SG&A Expenses | 13.32% | 15.77% | 11.70% | 14.05% | 1.60% |
| Depreciation & Amortization | 21.34% | 54.27% | 163.28% | 236.69% | 177.59% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.90% | 11.43% | 3.66% | -3.05% | -4.16% |
| Operating Income | -23.60% | 181.43% | 120.29% | 107.45% | 83.86% |
| Income Before Tax | -582.07% | 150.14% | 119.55% | 107.03% | 103.10% |
| Income Tax Expenses | 390.57% | 60.81% | -74.03% | -34.13% | 2.83% |
| Earnings from Continuing Operations | -1,570.01% | 143.89% | 117.64% | 105.21% | 101.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,570.01% | 143.89% | 117.64% | 105.21% | 101.52% |
| EBIT | -23.60% | 181.43% | 120.29% | 107.45% | 83.86% |
| EBITDA | -47.66% | 214.49% | 133.64% | 116.67% | 90.28% |
| EPS Basic | -1,881.02% | 140.26% | 116.50% | 104.65% | 101.12% |
| Normalized Basic EPS | -13.24% | 182.11% | 122.09% | 109.54% | 86.47% |
| EPS Diluted | -2,553.33% | 138.99% | 115.86% | 104.30% | 100.83% |
| Normalized Diluted EPS | -30.50% | 174.00% | 121.07% | 108.96% | 86.01% |
| Average Basic Shares Outstanding | 5.04% | 5.80% | 6.77% | 5.31% | 4.01% |
| Average Diluted Shares Outstanding | 8.44% | 12.18% | 11.93% | 9.05% | 6.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |